Flightpath Bio Launches via Illumina Accelerator for Largest Clinical Biomarker Study in Lyme Disease

BERKELEY, Calif., Feb 09, 2021 (SEND2PRESS NEWSWIRE) — Flightpath Biosciences, a life sciences company, launched today claiming a spot in Illumina Accelerator’s second global class to develop diagnostics and microbiome-targeted therapeutics to treat rare pathogen-driven diseases. The company has operated in stealth since its founding in mid-2019 and has built a pipeline of drug candidates for a wide range of diseases, starting with acute and Persistent Lyme Disease (PLD).
* Flightpath is led by an experienced team eager to execute deep data discovery and drive a pipeline of narrow-spectrum, targeted therapeutics into the clinic
* Company aims to combine deep genomic sequencing, metabolomics and immune-cell profiling with next generation machine-learning approaches to solve multiple pathogen-driven diseases and syndromes

Related Keywords

Berkeley ,California ,United States ,Matt Tindall ,Michael Bellas ,Twitter ,Flightpath Biosciences Inc ,Flightpath Biosciences ,Illumina Accelerator ,Persistent Lyme Disease ,Flightpath Co Founder ,Persistent Lyme ,Mark De Souza ,பெர்க்லி ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,மேட் டிண்டால் ,மைக்கேல் பெல்லாஸ் ,ட்விட்டர் ,இல்லுமின முடுக்குப்பொறி ,தொடர்ந்து லைம் நோய் ,தொடர்ந்து லைம் ,குறி டி ஸூஸ ,